Showing 2571-2580 of 9331 results for "".
Nonsurgical Skin Tightening and Facelifts
https://practicaldermatology.com/series/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/54266/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.DWTV Extra: Skin and Scalp Health
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-skin-and-scalp-health/54147/Chesahna Kindred, MD, MBA, FAAD, discusses an event at the Science of Skin & Scalp Studio in New York, New York, featuring interactive rooms led by dermatologists, beauty experts, and influencers living with chronic inflammatory conditions sharing stories and shaping the conversation around skinEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urImproving Care Options for CTCL
https://practicaldermatology.com/series/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.The Evolving Needs of the Modern Patient
https://practicaldermatology.com/series/c-suite-chats/the-evolving-needs-of-the-modern-patient/39900/Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs.Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-socioeconomic-neighborhood-status-linked-with-hs-severity-plus-more/39881/This episode highlights new data linking neighborhood socioeconomic status to hidradenitis suppurativa severity, as well as a new study of mitochondrial decline in skin cells leading to skin aging and even obesity. Also, a new Atopic Dermatitis Journal Club examines combination therapy with dupilumaDermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.The Battle of Biostimulators: PLLA vs Hyperdilute CaHA
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/the-battle-of-biostimulators-plla-vs-hyperdilute-caha/39250/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, hosts a workshop describing the differences between two dermal filler options, and how she utilizes both in her practice. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank oDWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aRegenerative Treatments in Dermatology
https://practicaldermatology.com/series/c-suite-chats/regenerative-treatments-in-dermatology/37707/John Aylworth, PhD, CEO and founder of Xytogen Biotech, talks about the growing demand for regenerative treatments in dermatology and new options for the treatment room.